Snapshot of Our World Class Speaker Faculty

Kenneth Rhodes

CSO

Yumanity

Matthew Townsend

Global Director of Proteostasis, Alzheimer's Disease

AbbVie

Michele Vendruscolo

Professor & CSO

Cambridge University Centre for Misfolding Diseases & Wren Therapeutics

Suchira Bose

Research Advisor & Head of Molecular Pathology, Neuroscience

Eli Lilly

Marcia Taylor

VP Research & Neurodegeneration Alliance Manager

Treventis

Neil Cashman

CSO & Co-Founder

ProMIS Neurosciences

Rick Morimoto

Professor

Northwestern University

Wagner Zago

CSO

Prothena

With protein misfolding and aggregation prevalent in neurodegeneration, cancer, metabolic and ophthalmic diseases, the unmet clinical need presents huge opportunity to accelerate the discovery and translation of novel therapeutics to transform patient outcomes. However, despite decades of clinical lessons, revived investment and scientific progress in understanding the molecular biology of protein misfolding disorders, there are still currently no approved disease-modifying therapies or cures available.

As such, the inaugural Protein Misfolding Drug Discovery Summit has been established as the only industry and translational focused forum for large pharma, innovative biotech and research institutes to shift the drug design discovery paradigm and seize the untapped therapeutic opportunity to target protein misfolding and aggregation.

Built with large pharma and biotech insights, this summit will unite drug discovery and development professionals to help validate novel druggable targets that underlie protein conformational diseases, improve preclinical predictability of patient derived models, optimize drug pharmacology and accelerate the translation of novel protein misfolding targeted therapeutics into the clinic.

View the full event guide for further details on speakers, content and how to join those who are re-defining the protein misfolding field.

Media Partners 2020

Capture

Other Events In The Undruggable Series